prl3-zumab
mAbexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 20, 2017 (NCT03191682)
Timeline
Indications
Mechanism of action
- Protein-tyrosine phosphatase 4A3INHIBITOR
PTP4A3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07290088 | Phase 2/Phase 3 (Phase 3) | Jan 9, 2023 | INTRA-IMMUSG PRIVATE LIMITED, Kuala Lumpur General Hospital, Univerisiti Sains Malaysia |
| NCT04452955 | Phase 2 | Dec 12, 2020 | INTRA-IMMUSG PRIVATE LIMITED, Parexel |
| NCT04118114 | Phase 2 | Sep 3, 2019 | Government of Singapore, INTRA-IMMUSG PRIVATE LIMITED |
| NCT03191682 | Phase 1 | Feb 20, 2017 | INTRA-IMMUSG PRIVATE LIMITED, National University of Singapore |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| INTRA-IMMUSG PRIVATE LIMITED | For profit | 4 | 2 | 3 | 2017 |
| Government of Singapore | Government | 1 | 1 | 1 | 2019 |
| Kuala Lumpur General Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Parexel | For profit | 1 | 0 | 1 | 2020 |
| Univerisiti Sains Malaysia | Academic/Hospital | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1